1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Orexo AB

Orexo AB

ORX.ST
Orexo ABSE flagStockholm Stock Exchange
24.35
SEK
+0.10
- -
855.34MMarket Cap
Orexo AB
ORX.ST
(Stockholm Stock Exchange)

Recent

price

24.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.99
7.35
11.08
14.3
17.46
18.74
20.47
18.64
22.66
24.4
19.29
16.46
18.17
18.56
0.86
0.75
3.63
Revenue per Share
-3.81
-14.43
-2.92
-5.16
-1.73
-6.09
0.84
0.67
3.99
6.33
-2.45
-6.51
-5.17
-3.73
-5.89
18.46
15.81
Basic EPS, GAAP
-1.98
-4.49
0.78
-12.35
-14.92
-3.28
4.49
4.2
6.9
7.37
-5.03
-8.21
-5.25
-3.32
-9.6
-5.64
-1.66
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-26.91
-37.52
-39.32
-43.7
-41.57
-45.44
-44.62
-43.87
-39.85
-33.45
-36.12
-42.72
-47.85
-51.49
-57.26
-38.9
- -
Book Value per Share
2.6
5.9
1.91
-1.11
6.39
3.32
4.99
6.02
10.77
17.11
8.89
2.94
-0.68
-3.32
-4.44
14.16
10.45
Tangible Book Value per Share
23
27
29
30
33
34
34
35
35
35
34
34
34
34
34
35
35
Basic Weighted Avg Shares
210
200
326
429
570
646
706
644
783
845
664
565
624
639
30
26
126
Sales/Revenue/Turnover
-42.53
-196.13
-24.34
-32.53
-4.38
-27.95
-3.47
3.01
9.87
26.12
-5.68
-39.81
-34.31
-16.97
-1,457.91
-1,310
-157.79
Operating Margin (%)
34
279
17
51
13
81
25
21
21
41
39
53
69
77
165
67
53
Depreciation Expense
-89
-392
-86
-155
-57
-210
29
23
138
219
-84
-224
-178
-128
-203
639
551
Net Income, GAAP
- -
- -
- -
- -
- -
- -
18.26
21.89
- -
3.86
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-42.4
-196.38
-26.32
-36.09
-9.92
-32.5
4.11
3.6
17.61
25.94
-12.72
-39.56
-28.45
-20.08
-683.5
2,458.85
435.65
Profit Margin (%)
124
238
124
47
678
571
516
478
576
760
230
485
350
196
215
850
241
Working Capital
94
115
114
104
494
494
398
319
321
323
47
530
519
453
466
484
3
LT Debt
468
311
191
161
468
270
310
329
476
706
558
350
194
59
-126
491
365
Total Equity
- -
- -
- -
- -
- -
- -
-2.71
2.22
- -
22.88
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-4.3
-3.45
- -
-25.43
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
8
4
LT Borrowings
- -
483
- -
LT Finance Leases
- -
1
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
1,144
1,043
761

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
1,165
476
Cash, Cash Equivalents & STI
- -
912
386
Accounts Receivable, Net
- -
185
17
Inventories
- -
- -
- -
Total Current Liabilities
- -
315
235
Payables & Accruals
- -
- -
- -
ST Debt
- -
8
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-86.14%
-190.89%
-488.44%
Free Cash Flow
-20.02%
27.86%
-41%
Net Income, GAAP
4.07%
-48.04%
-414.93%
Sales/Revenue/Turnover
-10.13%
-21.97%
-12.46%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
139
154
136
8
30
2025
13
118
- -
3
26
2026
5
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.26
-1.04
-1.21
-3.37
-5.89
2025
-0.46
-1.15
- -
20.88
18.46
2026
-3.81
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
KUKJE PHARMA Co., Ltd. (002720.KS)
Mera Pharmaceuticals, Inc. (MRPI)
Accent Microcell Limited (ACCENTMIC.NS)
Ligand Pharmaceuticals, Inc. (LGNDZ)
Oxurion N.V. (0G99.L)
H. Lundbeck A/S (HLUBF)
Business
Orexo AB (publ) (ORX.ST) is a Swedish specialty pharmaceutical company that develops and commercializes innovative pharmaceuticals and digital therapies primarily targeting opioid use disorder, addiction-related conditions, and other unmet medical needs using proprietary drug delivery technologies such as sublingual and nasal powder platforms. The company offers Zubsolv sublingual tablets for opioid dependence treatment; Abstral sublingual tablets for breakthrough cancer pain; Edluar sublingual tablets for short-term insomnia; and digital therapies including deprexis for depression, vorvida for alcohol use disorder, and modia for opioid use disorder; it also advances a pipeline featuring OX124 (iCIPRI) and OX125 as high-dose nasal naloxone and nalmefene rescue medications for opioid overdose, OX640 as a powder-based epinephrine nasal product for anaphylaxis, OX390 as an intranasal rescue medication for adulterated opioid overdoses, and OX-MPI for endometriosis in collaboration with Gesynta Pharma. Orexo operates through segments including US Pharma for commercial sales, Digital Therapeutics, and HQ/Pipeline for research, development, and out-licensing; it serves markets in the United States, European Union, United Kingdom, and internationally with a focus on patients, healthcare providers, and partners. Founded in 1994 and headquartered in Uppsala, Sweden, the company employs approximately 110 people and reported net sales of SEK 590 million in 2024. Recent developments include a September 2025 BARDA contract award of up to USD 50.9 million (initial USD 8 million) to Orexo US for OX390 development, conversion of future OX-MPI rights to SEK 19 million in Gesynta Pharma shares, preparation for Izipry (OX124) commercial launch as a nasal overdose rescue medication, ongoing partnering discussions and market research for OX640, a collaboration with Abera Bioscience on nasal powder vaccines using AmorphOX technology, and reaffirmation of 2025 positive EBITDA guidance amid Q3 revenue challenges.

Company News

APIChatGPT

  • prnewswire.com

    Invitation & Agenda: Orexo R&D Day on March 24